DK189484D0 - Steroidforbindelser af 20-spiroxanraekken og analoge deraf med aaben e-ring samt deres fremstilling og anvendelse - Google Patents

Steroidforbindelser af 20-spiroxanraekken og analoge deraf med aaben e-ring samt deres fremstilling og anvendelse

Info

Publication number
DK189484D0
DK189484D0 DK1894/84A DK189484A DK189484D0 DK 189484 D0 DK189484 D0 DK 189484D0 DK 1894/84 A DK1894/84 A DK 1894/84A DK 189484 A DK189484 A DK 189484A DK 189484 D0 DK189484 D0 DK 189484D0
Authority
DK
Denmark
Prior art keywords
spiroxan
analogue
series
preparation
ring
Prior art date
Application number
DK1894/84A
Other languages
English (en)
Other versions
DK163988C (da
DK189484A (da
DK163988B (da
Inventor
Juergen Grob
Jaroslav Kalvoda
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK189484D0 publication Critical patent/DK189484D0/da
Publication of DK189484A publication Critical patent/DK189484A/da
Publication of DK163988B publication Critical patent/DK163988B/da
Application granted granted Critical
Publication of DK163988C publication Critical patent/DK163988C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK189484A 1983-04-13 1984-04-12 9alfa,11alfa-epoxy-20-spiroxaner og analoge deraf med aaben tetrahydrofuranring e samt deres fremstilling og farmaceutiske praeparater indeholdende dem DK163988C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13
CH198183 1983-04-13

Publications (4)

Publication Number Publication Date
DK189484D0 true DK189484D0 (da) 1984-04-12
DK189484A DK189484A (da) 1984-10-14
DK163988B DK163988B (da) 1992-04-27
DK163988C DK163988C (da) 1992-09-21

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
DK189484A DK163988C (da) 1983-04-13 1984-04-12 9alfa,11alfa-epoxy-20-spiroxaner og analoge deraf med aaben tetrahydrofuranring e samt deres fremstilling og farmaceutiske praeparater indeholdende dem

Country Status (23)

Country Link
US (1) US4559332A (da)
EP (1) EP0122232B1 (da)
JP (1) JPS59231100A (da)
AR (4) AR241918A1 (da)
AT (1) ATE39256T1 (da)
AU (1) AU565017B2 (da)
CA (1) CA1220781A (da)
DD (2) DD251144A5 (da)
DE (2) DE3475622D1 (da)
DK (1) DK163988C (da)
ES (4) ES8602846A1 (da)
FI (1) FI77669C (da)
GR (1) GR81834B (da)
HU (1) HU191406B (da)
IE (1) IE57541B1 (da)
IL (1) IL71504A (da)
LU (1) LU91072I2 (da)
NL (1) NL300144I1 (da)
NO (1) NO159800C (da)
NZ (1) NZ207826A (da)
PH (1) PH19997A (da)
PT (1) PT78413B (da)
ZA (1) ZA842710B (da)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
ES2115665T3 (es) * 1991-01-29 1998-07-01 Shionogi & Co Derivado de triterpeno.
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
EP0831910B1 (en) * 1995-06-07 2001-11-21 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
EP1167381A3 (en) * 1995-12-11 2004-09-29 G.D. Searle & Co. Process for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and Intermediates useful therein
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
EP0973791B1 (en) * 1995-12-11 2007-06-20 G.D. Searle LLC. Process for the preparation of an epoxy compound
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
EP1148061B1 (en) * 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
BR9714510A (pt) 1996-12-11 2000-11-28 Searle & Co Processo e preparo de esteróides de 9,11-époxi e intermediários úteis dos mesmos
CA2298453A1 (en) * 1998-05-29 1999-12-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing seasoning liquors with flavor of vegetables pickled in salted rice bran paste
AU1714000A (en) * 1998-11-06 2000-05-29 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DK1140186T3 (da) * 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og derivater af fibrinsyre til hjertekar indikationer
JP2002533411A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための組み合わせ
ES2189529T3 (es) * 1998-12-23 2003-07-01 Searle Llc Combinaciones de inhiidores para el transporte de acidos biliares en el ileon y agentes complejantes para indicaciones cardiovasculares.
WO2000038723A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
BR9916565A (pt) 1998-12-23 2002-01-29 Searle Llc Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
MXPA01006471A (es) 1998-12-23 2004-03-10 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal e inhibidores de proteina de transferencia de ester colesterilio cpara indicaciones cardiovasculares.
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
HUP0203032A3 (en) * 1999-12-08 2003-04-28 Pharmacia Corp Chicago Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use
CN100413881C (zh) * 1999-12-08 2008-08-27 法马西亚公司 依匹乐酮晶形
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
DK1175220T3 (da) * 1999-12-08 2005-08-29 Pharmacia Corp Nanopartikulære eplerenonkompositioner
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
JP2003528830A (ja) 2000-03-10 2003-09-30 ファルマシア・コーポレーション テトラヒドロベンゾチエピン類の製造方法
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
EP1303306B1 (en) * 2000-07-27 2006-06-21 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
WO2002017895A2 (en) * 2000-08-28 2002-03-07 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
IL155529A0 (en) * 2000-10-30 2003-11-23 Pharmacia Corp Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
CA2428784A1 (en) * 2000-11-09 2002-05-16 Astrazeneca Ab Oral pharmaceutical composition containing a block copolymer
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
MXPA04003524A (es) * 2001-11-02 2004-07-23 Searle Llc Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
JP2005516914A (ja) 2001-12-12 2005-06-09 ファルマシア・コーポレーション エポキシ−ステロイド系アルドステロン受容体アンタゴニストで眼病を治療する方法
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
AU2003222009A1 (en) * 2002-03-18 2003-10-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
EP1485105A1 (en) * 2002-03-18 2004-12-15 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
EP1487540A2 (en) * 2002-03-20 2004-12-22 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
AU2003220251A1 (en) * 2002-03-22 2003-10-13 Pharmacia Corporation C-17 spirolactonization and 6,7 oxidation of steroids
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
EP1534732B1 (en) * 2002-08-16 2006-09-13 Pharmacia & Upjohn Company LLC 5 androsten-3-ol steroid intermediates and processes for their preparation
WO2004043987A1 (en) * 2002-11-06 2004-05-27 Pharmacia & Upjohn Company Llc Processes for preparing 7-carboxy substituted steroids
DE60312029T2 (de) * 2002-11-07 2007-06-21 Pharmacia & Upjohn Co. Llc, Kalamazoo Verfahren zur herstellung c-7 substituierter 5-androstene
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
RU2006133715A (ru) * 2004-03-22 2008-04-27 Фармаци энд Апджон Компани ЭлЭлСи (US) Усовершенствованный способ получения 9, 11-эпоксистероидов
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
WO2008074098A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
ES2523734T3 (es) 2009-05-28 2014-12-01 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2773079T3 (es) * 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
LT2956464T (lt) 2013-02-14 2018-07-10 Novartis Ag Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
EP3009443B1 (en) 2014-10-17 2018-09-12 INDUSTRIALE CHIMICA S.r.l. Process for the preparation of 7alfa-(methoxycarbonyl)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactone, a useful intermediate for the synthesis of molecules with pharmacological activity
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
US4559332A (en) 1985-12-17
CA1220781A (en) 1987-04-21
DK163988C (da) 1992-09-21
ATE39256T1 (de) 1988-12-15
DK189484A (da) 1984-10-14
ES8705460A1 (es) 1987-05-01
FI841400A0 (fi) 1984-04-09
NO159800B (no) 1988-10-31
IL71504A (en) 1987-07-31
EP0122232A1 (de) 1984-10-17
ES531517A0 (es) 1985-12-01
NO841465L (no) 1984-10-15
NZ207826A (en) 1986-07-11
JPS59231100A (ja) 1984-12-25
AR241918A1 (es) 1993-01-29
ES544768A0 (es) 1987-05-01
IL71504A0 (en) 1984-07-31
AR242223A1 (es) 1993-03-31
ES8705459A1 (es) 1987-05-01
LU91072I2 (fr) 2004-04-07
NO159800C (no) 1989-02-08
PT78413A (en) 1984-05-01
NL300144I2 (nl) 2004-06-01
DE122004000012I1 (de) 2012-05-16
FI841400A (fi) 1984-10-14
EP0122232B1 (de) 1988-12-14
GR81834B (da) 1984-12-12
ES8705461A1 (es) 1987-05-01
ES544770A0 (es) 1987-05-01
FI77669C (fi) 1989-04-10
ZA842710B (en) 1984-11-28
IE57541B1 (en) 1992-10-07
DE3475622D1 (en) 1989-01-19
AR242222A1 (es) 1993-03-31
HU191406B (en) 1987-02-27
NL300144I1 (nl) 2004-06-01
IE840906L (en) 1984-10-13
AR242221A1 (es) 1993-03-31
PH19997A (en) 1986-08-28
AU2685384A (en) 1984-10-18
DD251144A5 (de) 1987-11-04
PT78413B (en) 1986-08-22
ES8602846A1 (es) 1985-12-01
DE122004000012I2 (de) 2006-06-08
AU565017B2 (en) 1987-09-03
ES544769A0 (es) 1987-05-01
JPH0212479B2 (da) 1990-03-20
DD233375A5 (de) 1986-02-26
DK163988B (da) 1992-04-27
FI77669B (fi) 1988-12-30

Similar Documents

Publication Publication Date Title
DK189484D0 (da) Steroidforbindelser af 20-spiroxanraekken og analoge deraf med aaben e-ring samt deres fremstilling og anvendelse
DK205284D0 (da) Kompleksforbindelser af technetium-9m med alkylenaminoximer
DK371389A (da) Substituerede aminomethyltetraliner og deres heterocycliske analoge, deres fremstilling og anvendelse
DK554784A (da) Substituerede 5-amino-4-hydroxyvalerylderivater samt deres fremstilling og anvendelse
DK149546C (da) Filterenhed med et filterkammer og et deri anbragt filterelement samt anvendelse af en saadan filterenhed
NO791975L (no) Vinduer og fremgangsmaate og apparat for deres fremstilling
DK192986D0 (da) Tastatur med en anordning til variabel indstilling af tastaturets betjeningstryk
DK474782A (da) Inklusionskomplekser af steroider med gamma-cyclodextrin, deres fremstilling og anvendelse
DK154227C (da) Vandige pigmentdispersioner med et indhold af oxalkylerede novolakker og deres anvendelse
DK614084D0 (da) Milbemycim-derivater samt deres fremstilling og anvendelse
DK35884A (da) Lactampeptider samt deres fremstilling og anvendelse
DK38380A (da) Solfangerpanel og skraatag med saadanne paneler
DK294684D0 (da) N-alkylerede 3-phenyl-4-cyanopyrrol-derivater samt deres fremstilling og anvendelse
DK297082A (da) Substituerede 1-azolyl-2-hydroxy-alkanderivater samt deres fremstilling og anvendelse
DK199984D0 (da) Benzoyl-urinstof-derivater med insekticid-virkning og fremgangsmaade til fremstilling af saadanne derivater
DK71977A (da) Enolestere af steroider samt deres fremstilling og anvendelse
DK558484D0 (da) Milbemycinderivater samt deres fremstilling og anvendelse
DK314581A (da) Mellemprodukt i form af 17 (20) umaettede 20-isonitrilsteroider fremgangsmaade til deres fremstilling samt til deres anvendelse til fremstilling af 17alfa-hydroxy-20-ketoeroider
DK82687D0 (da) Hydroterapeutisk apparat med tilhoerende badekar
DK318278A (da) Beta-lactamforbindelser samt deres femstilling og anvendelse
DK297182A (da) Substituerede 2-hydroxy-3-azolyl-propanderivater samt deres fremstilling og anvendelse
DK152817C (da) Bladfjeder af kompositmateriale samt fremgangsmaade til fremstilling af samme
DK189584D0 (da) (5alfa)-20-spirox-1-en-3-oner samt deres fremstilling og anvendelse
DK219985A (da) Fremgangsmaade til fremstilling af kiselsyrerige poroese formlegemer samt deres anvendelse
DK233183A (da) Analoge af neurohypofysiske hormoner med haemmende effekt

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
PUP Patent expired
CTFF Application for supplementary protection certificate (spc) filed

Spc suppl protection certif: CA 2004 00006

Filing date: 20040407

Expiry date: 20090412

CTFW Supplementary protection certificate (spc) withdrawn, refused or deemed withdrawn

Free format text: PRODUCT NAME: EPLERENONE

Spc suppl protection certif: CA 2004 00006

Filing date: 20040407